COmplex BifuRcation Lesions: a Comparison Between the AXXESS Device and Culotte Stenting: an Optical Coherence Tomography (OCT) Study (COBRA)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Biosensors International
Information provided by (Responsible Party):
Prof Dr Walter Desmet, University Hospital, Gasthuisberg
ClinicalTrials.gov Identifier:
NCT01486095
First received: November 28, 2011
Last updated: January 20, 2014
Last verified: January 2014
  Purpose

Treatment of bifurcation lesions with drug-eluting stents (DES) (especially when a double stent technique is used) is associated with a higher risk for stent thrombosis. Different factors may play a role in the higher risk for stent thrombosis in bifurcation lesions. Possible mechanisms are delayed endothelialisation due to the action of the drug, coating polymers, or overlapping stent segments, incomplete stent apposition at specific sites in the bifurcation lesion and higher thrombogenicity due to turbulent flow at the bifurcation site. In human pathological data, the RUTSS (ratio of uncovered to total stent struts) appears to be the most powerful predictor of stent thrombosis.

This prospective study will assess the differences in stent strut coverage and stent strut apposition after complex bifurcation lesion treatment with the dedicated AXXESS Biolimus A9-eluting bifurcation stent at the bifurcation site and additional Biomatrix Biolimus A9-eluting stents in the distal main vessel and the side branch versus treatment with the culotte technique using the Xience Prime everolimus-eluting stents.


Condition Intervention Phase
True Coronary Bifurcation Lesions
Device: AXXESS + Biomatrix Biolimus Eluting stent
Device: Culotte technique with Xience V or Xience Prime stents
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison of Healing Responses After Treatment of Complex Bifurcation Lesions With a Dedicated Bifurcation Device (Axxess™ Drug Eluting Coronary Bifurcation Stent System + Biomatrix™ Drug Eluting Coronary Stent System Stents in the Distal Branches) Versus the Culotte Technique Using Xience Prime Everolimus-eluting Stents : an Optical Coherence Tomography (OCT) Analysis

Further study details as provided by Universitaire Ziekenhuizen Leuven:

Primary Outcome Measures:
  • Primary endpoint [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]
    Percent uncovered to total stent struts at 9 months, assessed with OCT, in two different bifurcation stenting techniques


Secondary Outcome Measures:
  • Secondary endpoint : stent strut coverage per segment with OCT [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]
    - Percent uncovered to total stent struts at 9 months per analyzed bifurcation segment (proximal MB, carina, distal MB, SB)

  • Secondary endpoint: stent strut apposition with OCT [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]
    - Percent malapposed to total stent struts at 9 months post procedure, both overall and per bifurcation segment

  • Secondary endpoint: clusters of malapposition with OCT [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]
    - Number of clusters of malapposition, overall and per bifurcation segment. Per cluster, the number of malapposed struts, the area (mm²), the volume (mm³) and the arc (degrees) of malapposition will be assessed.

  • Secondary endpoint: Tissue strut thickness with OCT [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]
    - Tissue strut thickness at 9 months per bifurcation segment (µm)

  • Secondary endpoint: neointimal hyperplasia volume [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]
    - Neointimal hyperplasia: absolute and percent volume of intimal hyperplasia at 9 months post procedure (mm³)

  • Secondary endpoint: late luminal loss (angiography) [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]
    - Late Lumen Loss (in-stent) at 9 months

  • Secondary endpoint: in-segment late luminal loss (angiography) [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]
    - In-segment Late Lumen Loss at 9 months (including stent + 5mm proximal and distal)

  • Secondary endpoint: binary restenosis (angiography) [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]
    - Binary in-stent restenosis at 9 months

  • Secondary endpoint: binary in-segment restenosis (angiography) [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]
    - Binary in-segment restenosis at 9 months (including stent + 5mm proximal and distal)

  • Secondary endpoint: minimal lumen diameter (angiography) [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]
    - Minimal Lumen Diameter (MLD), in-stent and in-segment at 9 months

  • Secondary endpoints: clinical: MACE [ Time Frame: 1, 8 and 12 months and annually for 5 years from the procedure date ] [ Designated as safety issue: Yes ]
    - Cumulative MACE rate (cardiac death, Q- or non-Q-wave MI, or clinically driven TLR) at 1, 8 and 12 months and annually for 5 years from the procedure date.

  • Secondary endpoints: clinical: components of MACE: cardiac death [ Time Frame: 1, 8 and 12 months and annually for 5 years from the procedure date ] [ Designated as safety issue: Yes ]
    - Cumulative components of MACE: cardiac death at 1, 8 and 12 months and annually for 5 years from the procedure date.

  • Secondary endpoints: clinical: components of MACE: Q- or non-Q-wave myocardial infarction [ Time Frame: 1, 8 and 12 months and annually for 5 years from the procedure date ] [ Designated as safety issue: Yes ]
    - Cumulative components of MACE :Q- or non-Q-wave MI at 1, 8 and 12 months and annually for 5 years from the procedure date.

  • Secondary endpoints: clinical: components of MACE: clinically driven target lesion revascularization (TLR) [ Time Frame: 1, 8 and 12 months and annually for 5 years from the procedure date ] [ Designated as safety issue: Yes ]
    - Cumulative components of MACE : clinically driven TLR at 1, 8 and 12 months and annually for 5 years from the procedure date.

  • Secondary endpoint: Stent thrombosis [ Time Frame: 24h, 1 month, 12 months and yearly thereafter (up to 5y) ] [ Designated as safety issue: Yes ]
    - Stent thrombosis at at 24h, 1 month, 12 months and yearly thereafter (up to 5y)

  • Secondary endpoint: Target vessel revascularization [ Time Frame: 1, 8, 12 months and yearly thereafter (up to 5y) ] [ Designated as safety issue: Yes ]
    - Target vessel revascularisation (TVR) at at 1, 8, 12 months and yearly thereafter (up to 5y)

  • Secondary endpoint: all-cause death [ Time Frame: 1, 8, 12 months and yearly thereafter (up to 5y) ] [ Designated as safety issue: Yes ]
    - All-cause death at 1, 8, 12 months and yearly thereafter (up to 5y)

  • Secondary endpoint: non-target revascularization [ Time Frame: 1, 8, 12 months and yearly thereafter (up to 5y) ] [ Designated as safety issue: Yes ]
    non-Target vessel revascularization at 1, 8, 12 months and yearly thereafter (up to 5y)

  • Secondary endpoint: any coronary revascularization [ Time Frame: 1, 8, 12 months and yearly thereafter (up to 5y) ] [ Designated as safety issue: Yes ]
    Any coronary revascularization 1, 8, 12 months and yearly thereafter (up to 5y)

  • Secondary endpoint: device success [ Time Frame: Immediately after initial treatment of the study lesion ] [ Designated as safety issue: Yes ]
    - Device success, defined as achievement of a final residual diameter stenosis of <30% measured by QCA.

  • Secondary endpoint: lesion treatment success [ Time Frame: Immediately after initial treatment of the study lesion ] [ Designated as safety issue: Yes ]
    - Lesion treatment success, defined as <30% residual stenosis in the MB and <50% in the SB measured by QCA by any treatment.

  • Secondary endpoint: procedure success [ Time Frame: 24h after treatment of the target lesion ] [ Designated as safety issue: Yes ]
    - Procedure success, defined as lesion success without the occurrence of MACE during the hospital stay.


Estimated Enrollment: 40
Study Start Date: November 2011
Estimated Study Completion Date: December 2017
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AXXESS + Biomatrix
After mandatory predilatation, a self-expanding, conically shaped nickel-titanium AXXESS biolimus A9-eluting stent is placed at the level of the carina. The device is available in 3.0 and 3.5 mm calibre and 11 and 14 mm length. Depending on the lesion anatomy, additional Biomatrix™ Drug Eluting Coronary Stent Systems are placed distally if necessary. The procedure is completed with kissing balloon postdilatation using non-compliant balloons sized to the reference vessel diameter of the distal branches. Before this kissing balloon inflation, consecutive high pressure inflations should be performed in both branches.
Device: AXXESS + Biomatrix Biolimus Eluting stent
NAP
Active Comparator: Culotte technique: Xience V/Prime
The culotte technique consists of stenting one of both branches of the bifurcation lesion first, and after balloon dilatation of the stent meshes, stenting the uncovered branch through the first stent and leaving the main vessel covered with two overlapped stents. The procedure is terminated by kissing balloon dilatation of both branches using non-compliant balloons sized to the reference vessel diameter of the distal branches. Before this kissing balloon inflation, consecutive high pressure inflations should be performed in both branches.
Device: Culotte technique with Xience V or Xience Prime stents
NAP

Detailed Description:

BACKGROUND: There is an ongoing controversy over the efficacy and safety of different bifurcation stenting techniques. Critical considerations are the rate of restenosis at the side branch ostium, and completeness of healing at sites of overlap of stent struts, which may affect the risk of stent thrombosis.

AIMS: To compare vessel healing at 9 months using OCT imaging for two different treatment techniques for treating bifurcation lesions. Quantitative assessment of OCT images will be used to assess re-endothelialisation and quality of strut apposition to the vessel wall.

METHODS: Patients with true bifurcation lesions with involvement of a significant side branch requiring a stent will be randomly assigned to one of two treatment strategies. Group A will comprise 20 patients which will be treated with the Axxess™ Drug Eluting Coronary Bifurcation Stent System (Biosensors Europe SA) where additional Biomatrix™ Drug Eluting Coronary Stent Systems (Biosensors Europe SA) are implanted into the distal main branch (MB) and the side branch (SB) as required. Group B will consist of 20 patients which will be treated with the culotte technique using Xience Prime everolimus-eluting stents (Abbott-Vascular, US). Kissing balloon dilatation using non-compliant balloons will complete the index procedure in all cases. At 9 months, control angiography for all patients (with QCA using dedicated software) and OCT (of both main vessel and side branch) will be performed.

ENROLMENT PLAN:

Start: Third quarter of 2011 Enrolment period: ± 12 months Clinical follow-up: 5 years Angiographic and OCT results expected third quarter of 2013

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient older than 18 years
  2. The subject has stable or unstable angina pectoris, or a positive functional study for ischemia.
  3. The subject is eligible for PCI, and is an acceptable candidate for coronary artery bypass surgery.
  4. The subject is male, or if female, has no childbearing potential or has had a negative urine or serum pregnancy test within 7 days of the index procedure and has no intention to become pregnant within a year of the procedure.
  5. The subject has signed the informed consent prior to the procedure, and agrees to comply with the follow up requirements.
  6. Patients with a de novo and true coronary bifurcation lesion (Medina classification (1,1,1), (1,0,1) or (0,1,1)).
  7. Coronary artery with proximal parent vessel reference diameter of 2.75 - 3.75 mm and a branch vessel diameter of ≥ 2.25 mm.
  8. The lesion must be at least 50% diameter stenosis within either the MB or SB.
  9. Regarding lesion length: lesion should be able to be covered by 2 Xience Prime stents in a Culotte technique, or by a combination of maximally 1 AXXESS and 2 Biomatrix™ Drug Eluting Coronary Stents.
  10. The side branch ostium is located at least 12 mm from the left main coronary artery.
  11. The angle between the sidebranch and the parent vessel is less than 70°.

Exclusion Criteria:

  1. Left ventricular ejection fraction of < 30%
  2. Impaired renal function (serum creatinine > 2.0 mg/dl)
  3. Previous and/or planned brachytherapy of target vessel
  4. Lesion of the left main trunk > 50%, unprotected
  5. The target vessel contains intraluminal thrombus.
  6. The target lesion shows angiographic evidence of moderate to severe calcification or tortuosity.
  7. Known allergies to antiplatelet, anticoagulation therapy, contrast media, everolimus or biolimus, stainless steel, cobalt, chromium, nickel or titanium
  8. Pregnant and/or breast-feeding females or females who intend to become pregnant (pregnancy test required)
  9. Patients with a life expectancy of less than one year
  10. Patient currently enrolled in other investigational device or drug trial
  11. Patient not able or willing to adhere to follow-up visits
  12. Patients who intend to have a major surgical intervention within 6 months of enrolment in the study.
  13. Patients who previously participated in this study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01486095

Locations
Belgium
ZOL Genk
Genk, Belgium, 3600
UH Leuven
Leuven, Belgium, 3000
Sponsors and Collaborators
Universitaire Ziekenhuizen Leuven
Biosensors International
Investigators
Principal Investigator: Christophe L Dubois, MD, PhD University Hospital Leuven, Leuven, Belgium
  More Information

No publications provided

Responsible Party: Prof Dr Walter Desmet, Christophe Dubois, MD, PhD, Principal Investigator, University Hospital, Gasthuisberg
ClinicalTrials.gov Identifier: NCT01486095     History of Changes
Other Study ID Numbers: UH Leuven S53441
Study First Received: November 28, 2011
Last Updated: January 20, 2014
Health Authority: Belgium: Institutional Review Board

ClinicalTrials.gov processed this record on April 16, 2014